Albers FC, Papi A, Taillé C, et al. - In this post hoc meta-analysis of data from two phase 3 clinical trials, MENSA and MUSCA, researchers evaluated the effectiveness of mepolizumab (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma, based on the bodyweight/BMI. For this investigation, they randomized patients (aged ≥ 12 years) with severe eosinophilic asthma and a history of exacerbations to 4-weekly placebo, mepolizumab 75 mg IV or 100 mg SC (MENSA), or placebo or mepolizumab 100 mg SC (MUSCA) for 32 (MENSA) or 24 (MUSCA) weeks. In total, 936 individuals received placebo or mepolizumab 100 mg SC. In patients with severe eosinophilic asthma, treatment with mepolizumab 100 mg SC demonstrated consistent clinical benefits across a range of body weights and BMIs. The investigators concluded that mepolizumab's fixed-dose scheme may be appropriate without the need for weight-based dosage.